… The flowchart of patient enrollment and the associations of ACE (angiotensin-converting
enzyme) inhibitors and angiotensin II receptor blockers (ARBs) with 28-d all-cause death of …

… comparing the effects of both ACE inhibitors … angiotensin converting enzyme inhibitors)
reduce all-cause mortality (HR. 0.89-0.91, p<0.05), whereas ARB (angiotensin II type 1 receptor …

Rationale: Use of ACEIs (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin
II receptor blockers) is a major concern for clinicians treating coronavirus disease 2019 (…

… 2 summarizes the baseline characteristics of COVID-19 patients and provides a comparison
… .12, 14 On the other hand, angiotensin II takes part in the immune response to acute …

With the capability of inducing elevated expression of ACE2 (angiotensin-converting enzyme
2), the cellular receptor for severe acute respiratory syndrome coronavirus 2, angiotensin II …

… It has long been suggested that angiotensin‐converting enzyme inhibitors ( ACE i) and
angiotensin II receptor blockers ( AT 2s) have some degree of ‘cross‐reactivity' in causing …

… Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (…
For example, ACEI reduced the degradation of bradykinin by angiotensin-converting enzyme …

… 2 binds to the extracellular domain of the transmembrane angiotensin-converting enzyme 2
(ACE2) receptor … For comparison of demographic variables and comorbidities among cohorts…

… -(1–7) acts as a counter-regulatory peptide by attenuating the deleterious effects of
angiotensin II, namely vasoconstriction, sodium retention and fibrosis. ACE2 is a transmembrane …

… and observational findings about the effect of ACEIs and ARBs on patients with COVID-19.
Given the impossibility of obtaining reliable estimates of comparative effectiveness in …